Hayes Meg

Hayes Meg currently serves as a Non-Executive Director at PHARNEXT, where she plays a pivotal role in shaping the company's strategic direction within the biotech and neurodegenerative disease sectors. Leveraging her extensive experience in investment management and analysis, Hayes provides invaluable oversight on governance frameworks, ensuring that PHARNEXT maintains the highest standards of transparency, compliance, and financial integrity. Her expertise in risk assessment and industry trend analysis enables her to offer forward-looking insights that support the company's long-term growth initiatives, particularly in the highly dynamic and competitive landscape of biotech innovation.

In her role, Hayes actively collaborates with executive management to refine strategic plans, evaluate potential M&A opportunities, and optimize resource allocation. Her deep understanding of investor relations and performance management helps foster strong stakeholder confidence, which is crucial for securing funding and strategic partnerships. Additionally, her leadership in overseeing financial reporting and budgetary decisions ensures that PHARNEXT remains aligned with its mission to develop groundbreaking therapies, while maintaining fiscal discipline.

Hayes’s broad skill set in investment governance and cross-sectoral collaboration complements her focus on advancing PHARNEXT’s scientific and commercial objectives. Her strategic guidance not only supports operational excellence but also accelerates the company’s capacity to innovate and bring transformative treatments to market. With her comprehensive industry insight and dedication to fostering sustainable growth, Hayes Meg continues to be a vital contributor to PHARNEXT’s success in the evolving landscape of biotech and life sciences.